Trial Profile
A Single Center, Randomized, Phase II Study of the combination of Cisplatin and Gemcitabine with or without Tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic biliary tract cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- Acronyms BILTRACTO
- 16 Dec 2020 Planned End Date changed from 11 Feb 2026 to 11 Jan 2030.
- 13 May 2019 New trial record